roche holding ag amgen patents decision blocks sales of mircera reuters u s health officials approved roche holding ags anemia fighting drug mircera a food and drug administration spokeswoman said but roche has said it wont launch the drug in the u s after a boston jury found the patents on amgen inc s top selling anemia drugs to be valid the decision effectively blocks mircera sales in the u s roche which had expected a u s green light for mircera hasnt yet decided whether to appeal the amgen ruling roche chief executive franz humer said earlier this week the company could wait until amgens patents expire before launching its drug mr humer added 
